Nuveen LLC Purchases Shares of 112,483 Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Nuveen LLC has acquired 112,483 shares of Y-mAbs Therapeutics, valued at approximately $498,000, representing about 0.25% ownership of the company.
• Several analysts have downgraded Y-mAbs Therapeutics' stock ratings to "hold" and set the price target at $8.60, reflecting a significant decrease from previous estimates.
• The company reported a positive EPS of ($0.07), exceeding analyst expectations, with quarterly revenue of $19.52 million against estimates of $18.40 million.

Nuveen LLC bought a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 112,483 shares of the company's stock, valued at approximately $498,000. Nuveen LLC owned 0.25% of Y-mAbs Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Paradigm Biocapital Advisors LP boosted its holdings in shares of Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock worth $33,171,000 after buying an additional 150,000 shares during the period. Northern Trust Corp boosted its holdings in shares of Y-mAbs Therapeutics by 6.5% during the 4th quarter. Northern Trust Corp now owns 359,223 shares of the company's stock worth $2,813,000 after buying an additional 21,936 shares during the period. Infinitum Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth about $1,218,000. Federated Hermes Inc. boosted its holdings in shares of Y-mAbs Therapeutics by 245.0% during the 1st quarter. Federated Hermes Inc. now owns 153,453 shares of the company's stock worth $680,000 after buying an additional 108,979 shares during the period. Finally, Bank of America Corp DE boosted its holdings in Y-mAbs Therapeutics by 59.5% in the 4th quarter. Bank of America Corp DE now owns 127,159 shares of the company's stock valued at $996,000 after purchasing an additional 47,439 shares during the period. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Price Performance

YMAB stock traded down $0.01 during trading on Tuesday, reaching $8.59. 177,807 shares of the company were exchanged, compared to its average volume of 534,915. The company has a 50-day moving average of $6.50 and a two-hundred day moving average of $5.29. The company has a market capitalization of $390.10 million, a price-to-earnings ratio of -17.17 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. The business had revenue of $19.52 million during the quarter, compared to analysts' expectations of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. On average, analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on YMAB shares. HC Wainwright reissued a "neutral" rating and issued a $8.60 price objective (down previously from $11.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, August 6th. Canaccord Genuity Group downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and cut their price objective for the company from $26.00 to $8.60 in a report on Tuesday, August 5th. Brookline Capital Management downgraded shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Truist Financial set a $8.60 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Finally, Morgan Stanley set a $8.60 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Eight investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus target price of $9.62.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.